Business Wire

BIOGEN-IDEC

Del
Biogen Idec Announces Official Partnership with Sailing Sclerosis’ “Oceans of Hope” to Globally Change Perceptions of MS

In celebration of World MS Day and as part of its ongoing mission to support those living with Multiple Sclerosis ( MS) globally, Biogen Idec (NASDAQ: BIIB) announced that it has joined the Sailing Sclerosis Foundation’s (SSF) Oceans of Hope project as principal sponsor and official partner. This multi-year, global campaign is designed to use sailing as a means to educate and empower the MS community, changing perceptions of what it means to live with the disease and demonstrating the benefits of an active lifestyle.

The Oceans of Hope project was pioneered by Dr. Mikkel Anthonisen, Founder of SSF and a MS specialist at Copenhagen University Hospital, Rigshospitalet. He and several other crew members, including some living with MS, will sail around the world, building strong bonds with the global MS community.

“We are proud to be a part of the Oceans of Hope project, which fits perfectly with our more than three decade commitment to supporting the MS community through innovative science and patient programs,” said David Allsop, senior vice president, Europe and Canada for Biogen Idec. “Treatment of MS needs to be holistic – incorporating the right therapies with community programs and resources. Through its message of empowerment, we believe that Oceans of Hope can benefit thousands of patients around the world.”

The campaign will kick off today in Copenhagen, Denmark with the official naming of the boat. It will officially launch from Copenhagen on June 15, after which the boat will stop in multiple harbors in Europe, North America, South America, and Australia. Each port day will be celebrated with an interactive event, giving people living with MS the opportunity to learn to sail and participate as crew members.

"We are delighted to partner with Biogen Idec. Oceans of Hope aims to change perceptions of MS by showing what is possible when people with a chronic disease are empowered to conquer their individual challenges,” said Dr. Anthonisen. “As a physician, I see that each person who has MS is unique and needs access to different resources to treat their individual disease. The voyage will also carry this year's World MS Day theme of access across the globe, building stronger bonds across the global MS and sailing communities."

For more information about Oceans of Hope and SSF, where the boat will stop, or how to participate in the program, please visit: www.sailingsclerosis.com . The boat’s voyage can be followed via SSF social media either via Twitter @sailsclerosis, Facebook at www.facebook.com/OceansofHope , and Instagram at OceansofHope.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system, which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity and specific symptoms of MS are unpredictable and vary from one person to another. MS affects more than 2.3 million people worldwide,1 with more than 500,000 sufferers in the European Union.2 Relapsing forms of MS include: relapsing-remitting MS (RRMS), the most common form of the disease accounting for 85 percent of cases, which is characterized by clearly defined acute attacks with full recovery or with residual deficit upon recovery;3 and progressive-relapsing MS, which affects 5 percent of people with MS and is characterized by steadily worsening disease from the beginning with occasional acute attacks like those experienced by people with RRMS.4

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com .

Biogen Idec is also on Twitter (@biogenidec): www.twitter.com/biogenidec

References

1 Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS . Page 8. Date Accessed: Mar. 17, 2014. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1

2 Multiple Sclerosis International Federation. Atlas of MS 2013. Epidemiology of MS . Date Accessed: Mar. 17, 2014. http://www.atlasofms.org/query.aspx

3 NMSS. Relapsing-Remitting MS . Date accessed: Mar. 17, 2014. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS

4 NMSS. Progressive-Relapsing MS. Date accessed: March 17, 2014. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Progressive-relapsing-MS

Contact:

Biogen Idec International
Shannon Altimari, +41 41 392 16 77
publicaffairs.EU@biogenidec.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 202524.7.2025 23:02:00 CEST | Press release

- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. “We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data undersc

DNIB.com Reports Internet Has 371.7 Million Domain Name Registrations at the End of the Second Quarter of 202524.7.2025 23:01:00 CEST | Press release

VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the second quarter of 2025 closed with 371.7 million domain name registrations across all top-level domains (TLDs), an increase of 3.3 million domain name registrations, or 0.9% compared to the first quarter of 2025. Domain name registrations also increased by 9.3 million, or 2.6%, year over year. The .com and .net TLDs had a combined total of 170.5 million domain name registrations in the domain name base at the end of the second quarter of 2025, an increase of 0.7 million domain name registrations, or 0.4% compared to the first quarter of 2025. The .com and .net TLDs had a combined decrease of 0.1 million domain name registrations, or 0.1%, year over year. As of June 30, 2025, the .com domain name base totaled 157.9 million domain name registrations and the .net

SES and the Luxembourg Government to Develop and Launch New Defence Satellite for GovSat24.7.2025 18:55:00 CEST | Press release

GovSat-2 is aimed at meeting growing demand for highly secure, flexible MILSATCOM services SES and the Luxembourg Government today announced their plan for development of a second satellite for GovSat (LuxGovSat S.A.), the public-private partnership and 50/50 joint venture between SES and the Luxembourg Government that provides secure, reliable and accessible satellite communication services for governments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724379713/en/ GovSat-2. Copyright: Thales Alenia Space GovSat-2 will be positioned over the European satellite arc. It will join GovSat-1 in augmenting reliable connectivity services for government customers over the region. The satellite will be built by Thales Alenia Space on its Spacebus 4000B2 platform. Since launching in 2018, the joint venture’s first defence satellite, GovSat-1, operated by GovSat from a secure missions operations centre in Luxembourg, has supporte

Infobip Named a Leader in 2025 Gartner® Magic Quadrant™ for Communications Platform-as-a-Service for the Third Consecutive Year24.7.2025 18:21:00 CEST | Press release

Infobip positioned furthest in Completeness of Vision Global communications platformInfobiphas once again been named a Leader in the 2025 Gartner Magic Quadrant for Communications Platform-as-a-Service (CPaaS)1. This year the company is placed furthest in Completeness of Vision. Infobip views this third consecutive recognition as acknowledging its status as a global CPaaS powerhouse. Magic Quadrant2 reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables customers to get the most from market analysis in alignment with their unique business and technology needs. As a Leader, Infobip is recognized for both its Ability to Execute and its Completeness of Vision. Infobip powers conversations for some of the

Andersen Consulting fremmer digitale transformationsmuligheder med eksponentielle digitale løsninger24.7.2025 17:43:00 CEST | Pressemeddelelse

Andersen Consulting fortsætter med at opbygge sin digitale konsulentplatform gennem et samarbejde med Exponential Digital Solutions (10xDS), et firma der specialiserer sig i AI-drevet transformation og nye teknologier. 10xDS blev stiftet i 2016 af adminstrerende direktør Binu Koshy og leverer next generation-løsninger inden for automatisering, analyse, kunstig intelligens, cybersikkerhed og udvikling af digitale produkter. Virksomhedens tværfaglige tilgang kombinerer teknisk ekspertise med strategisk indsigt og støtter kunderne i deres implementering og skalering af next generation-løsninger. Med international erfaring inden for forskellige brancher arbejder 10xDS på at løse operationelle ineffektiviteter og skabe ny værdi gennem digital innovation. "Hos 10xDS har vi opbygget en organisation, der er baseret på innovation og troen på, at AI og nye teknologier kan føre til betydeligt bedre forretningsresultater," siger Binu. "Dette samarbejde understøtter vores mission om at skalere tran

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye